-transparent.png){kind=logo}
We have carried out an investigation to determine whether or not the sister-chromatid exchange frequencies (SCEs) observed in bone marrow cells in mice treated with mitomycin C (MMC) are inhibited by the immunopotentiators Krestin and Lentinan. We found that mitomycin C (2 mg/kg, i.v.)-induced SCEs were inhibited in 27% of the mice treated with Krestin (300 mg/kg, i.p.) and in 23% of the mice treated with Lentinan (1 mg/kg, i.p.). The effects of Krestin were found to be dose-dependent in inhibition of MMC-induced SCEs while those of Lentinan were not. Our findings therefore suggest that Krestin and Lentinan are not only useful for cancer treatment as immunopotentiators in combination with anticancer drugs but may also prevent the increase of chromosomal damage induced by anticancer drugs.
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
February 1992,
Journal of toxicology and environmental health,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
June 1986,
Cancer research,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
March 1998,
Mutation research,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
January 1984,
Environmental mutagenesis,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
January 1989,
Environmental and molecular mutagenesis,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
January 1983,
Teratogenesis, carcinogenesis, and mutagenesis,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
July 1978,
Experimental cell research,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
February 1978,
Human genetics,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
January 1979,
Cytogenetics and cell genetics,
J Hasegawa, and
M Hosokawa, and
F Okada, and
H Kobayashi
June 2002,
Toxicology letters,
